|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 900 7th STREET, NW |
Address2 | Suite 750 |
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 72111-188
|
||||||||
|
6. House ID# 359400009
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Tracy Spicer, Principal |
Date | 04/18/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 1474 Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007
HR 2567 Medicare Home Infusion Therapy Coverage Act of 2007
HR 2606 340B Program Improvement and Integrity Act of 2007
HR 2914 Medicare IVIG Access Act of 2007
HR 3932 Medicare Prescription Drug Savings and Choice Act of 2007
HR 4296 Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007
S 870 Medicare Home Infusion Therapy Consolidated Coverage Act of 2007
S 1376 340B Program Improvement and Integrity Act of 2007
S 1507 Access to Medicare Data Act of 2007
S 1544 Medicare Quality Enhancement Act of 2007
Competitive Bidding
Contract Disclosure Regulations
Comparative Effectiveness
340B Program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Spicer |
|
|
|
Amy |
Tejral |
|
|
|
Laurie |
Sullivan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
HR 971 Community Pharmacy Fairness Act of 2007
HR 2970 Pharmacy Benefit Manager Transparency Act of 2007
HR 3140 Saving Our Community Pharmacies Act of 2007
HR 3090 Patient and Pharmacy Protection Act of 2007
HR 3193 Access to Community Pharmacy Preservation Act of 2007
S 885 Community Pharmacy Fairness Act of 2007
S 980 Online Pharmacy Consumer Protection Act of 2007
S 1827 Pharmacist Access and Recognition in Medicare (PhARM) Act of 2007
S 1954 Pharmacy Access Improvement (PhAIm) Act of 2007
S 2013 Patient and Pharmacy Protection Act of 2007
S 2085 Patient and Pharmacy Protection Act of 2007
S 2161 Community Pharmacy Fairness Act of 2007
Internet Pharmacies
Off-Label Use of Prescription Drugs.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Spicer |
|
|
|
Amy |
Tejral |
|
|
|
Laurie |
Sullivan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR 380 Pharmaceutical Market Access and Drug Safety Act of 2007
HR 493 Genetic Information Nondiscrimination Act of 2007
HR 1368 Personalized Health Information Act of 2007
HR 1432 Preserve Access to Affordable Generics Act
HR 1666 Health Care Price Transparency Promotion Act of 2007
HR 1902 Protecting Consumer Access to Generic Drugs Act of
HR 1956 Patient Protection and Innovative Biologic Medicines Act of 2007
HR 3800 Promoting Health Information Technology Act
H.R. 5629 Pathway for Biosimilars Act
S 28 Generics First Act of 2007
S 242 Pharmaceutical Market Access and Drug Safety Act of 2007
S 251 Pharmaceutical Market Access Act of 2007
S 273 Prescription Drug and Health Improvement Act of 2007
S 316 Preserve Access to Affordable Generics Act
S 358 Genetic Information Nondiscrimination Act of 2007
S 596 Safe Internet Pharmacy Act of 2007
S 628 Critical Access to Health Information Technology Act of 2007
S 976 Genomics and Personalized Medicine Act of 2007
S 1408 Health Information Technology Act of 2007
S 1455 National Health Information Technology and Privacy Advancement Act of 2007
S 1505 Affordable Biologics for Consumers Act
S 1693 Wired for Health Care Quality Act
S 1695 Biologics Price Competition and Innovation Act of 2007
S. 1814 Health Information Privacy and Security Act
S 2408 Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007
Health Information Technology
Electronic Prescribing
Genetic Nondiscrimination
Inappropriate use of Human Growth Hormone
Confidentiality of Health Information
Generic Drugs
Generic Biologics
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Spicer |
|
|
|
Amy |
Tejral |
|
|
|
Laurie |
Sullivan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |